Thanks for the info, lonely. I didn't hear the cc, but I knew there was a problem when 9 weeks into the trial they hadn't even averaged 1 patient per week per site.
The device just monitors blood glucose, so it can't cure anyone. I would think that most patients spend at least 24 hours in ICU.
Besides my irritation over the multiple financings, ECTE has now turned into a company with a drifting timetable for milestones. Only a few months ago the US trial was supposed to wrap up in Q4 of 2013. I'm guessing it won't start until 2014.
I take it that the partnership offers don't include cash upfront to fund a US trial. And the EU rollout will cost money as well.
What's their game plan - wait for EU approval and then do a large secondary on the bounce? Or can they even hold out that long?
News 
Market Data 
Discover 
AI
